References
- Flume PA , Mogayzel PJ , Robinson KA , Goss CH , Rosenblatt RL , Kuhn RJ , et al.Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med. 2009;180(9):802–8.
- Prescott WA Jr . National survey of extended-interval aminoglycoside dosing in pediatric cystic fibrosis pulmonary exacerbations. J Pediatr Pharmacol Ther. 2011;16(4):262–9.
- Prescott WA Jr . A survey of extended-interval aminoglycoside dosing practices in United States adult cystic fibrosis programs. Respir Care. 2014;59(9):1353–9.
- Begg EJ , Barclay ML , Duffull S . A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol. 1995;39:605–9.
- Beringer PM , Vinks AA , Jelliffe RW , Shapiro BJ . Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration. Antimicrob Agents Chemother. 2000;44(4):809–13.
- Young DC , Zobell JT , Stockmann C , Waters CD , Ampofo K , Sherwin CMT , et al.Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V aminoglycosides. Pediatr Pulmonol. 2013;48:1047–61.
- Master V , Roberts GW , Coulthard KP , Baghurst PA , Martin A , Roberts ME , et al.Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbation of cystic fibrosis. Pediatr Pulmonol. 2001;31:367–76.
- Burkhardt O , Lehmann C , Madabushi R , Kumar V , Derendorf H , Welte T . Once-daily tobramycin in cystic fibrosis: better for clinical outcomes than thrice-daily tobramycin but more resistance development? J Antimicrob Chemother. 2006;58:822–9.
- Bragonier R , Brown NM . The pharmacokinetics and toxicity of once-daily tobramycin therapy in children with cystic fibrosis. J Antimicrob Chemother. 1998;42:103–6.
- Lam W , Tjon J , Seto W , Dekker A , Wong C , Atenafu E , et al.Pharmacokinetic modelling of a once-daily dosing regimen for intravenous tobramycin in paediatric cystic fibrosis patients. J Antimicrob Chemother. 2007;59:1135–40.
- Schwartz GJ , Munoz A , Schneider MF , Mak RH , Kaskel F , Warady BA , et al.New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20:629–37.
- Sawchuk RJ , Zaske DE . Pharmokinetics of dosing regimens which utilize mutiple intravenous infusions: gentamicin in burn patients. J Pharmacokinet Biopharm. 1976;4:183–95.
- Akcan-Arikan A , Zappiteli M , Loftis LL , Washburn KK , Jefferson LS , Goldstein SL . Modified RIFLE criteria in critically ill children with acute kidney injury. Kidney Int. 2007;71:1028–35.
- Stallings VA , Stark LJ , Robinson KA , Feranchak AP , Quinton H . Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review. J Am Diet Assoc. 2008;108:832–9.
- Touw DJ , Vinks AA , Heijerman HG , Bakker W . Validation of tobramycin monitoring in adolescent and adult patients with cystic fibrosis. Ther Drug Monit. 1993;15:52–9.
- Vic P , Ategbo S , Turck D , Husson MO , Launay V , Loeuille GA , et al.Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis. Arch Dis Child. 1998;78:536–9.
- Wood PJ , Ioannides-Demos LL , Li SC , Williams TJ , Hickey B , Spicer WJ , et al.Minimisation of aminoglycoside toxicity in patients with cystic fibrosis. Thorax. 1996;51:369–73.
- Henning S , Norris R , Kirkpatrick CM . Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis – a population pharmacokinetic study. Br J Clin Pharmacol. 2008;65:502–10.
- Zobell JT , Ampofo K , Cash J , Korgenski K , Chatfield BA . High dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients. J Cyst Fibros. 2010;9(4):280–3.
- Burgess LD , Drew RH . Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam. Pharmacotherapy. 2014;34:670–6.
- Gomes DM , Smotherman C , Birch A , Dupree L , Della Vecchia BJ , Kraemer DF , et al.Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime. Pharmacotherapy. 2014;34:662–9.